MYCOLab Ai Logo - gold and army green

The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics

Summary

Researchers created a new questionnaire called the Afterglow Inventory to measure the positive effects people experience in the days and weeks after using psychedelics like psilocybin and LSD. These ‘afterglow’ effects include improved mood, feelings of spiritual connection, increased creativity, and better relationships. The study with over 1,300 participants showed the questionnaire works well at measuring these effects, which could help researchers better understand how psychedelics might help treat depression and other conditions.

Background

Classic psychedelics such as psilocybin and LSD are associated with a phenomenon called ‘psychedelic afterglow,’ characterized by predominantly pleasant, temporary psychological effects reported after acute effects subside. Post-acute effects are crucial for therapeutic applications of psychedelics, yet no systematic instrument exists to assess these subacute afterglow effects.

Objective

To create and validate a questionnaire (Afterglow Inventory) to quantify the subacute afterglow effects of classic serotonergic psychedelics. The instrument aims to better understand the interplay between acute, subacute, and long-term effects across different substances, dosages, and therapeutic contexts.

Results

A 5-factor structure with 24 items best fit the data: vitality, transpersonal aspects, inspiration/creativity, interpersonal relationships, and relationship to nature. The AGI effectively differentiated between psychedelic and control groups. Overall AGI scores positively correlated with intensity and positive valence of acute effects, with ayahuasca showing strongest and 2C-B showing weakest afterglow effects.

Conclusion

The AGI is a novel, validated scale for quantifying positive subacute afterglow effects of psychedelics. The instrument could improve understanding of how different substances, dosages, and extra-pharmacological factors like psychotherapy influence psychedelic outcomes and therapeutic potential.
  • Published in:Journal of Psychopharmacology,
  • Study Type:Validation Study,
  • Source: PMID: 40165350, DOI: 10.1177/02698811251326937
Scroll to Top